## Summary
The paper introduces IgSeek, a novel framework for antibody sequence design that leverages structure retrieval to enhance accuracy and reliability. IgSeek employs a multi-channel equivariant graph neural network to construct a CDR vector database, which is then used to predict CDR sequences from templates retrieved from isomorphic structures. The authors demonstrate the effectiveness and efficiency of IgSeek through extensive experiments, showcasing its potential for de novo antibody sequence design.

## Strengths
The paper presents several strengths, including:
* A novel approach to antibody sequence design that addresses the challenges of hallucinations in protein inverse folding
* A well-designed multi-channel equivariant graph neural network that effectively captures structural information in CDR loops
* Extensive experiments that demonstrate the superiority of IgSeek over state-of-the-art methods in terms of sequence recovery and inference speed
* A clear and well-organized presentation of the methodology and results, making it easy to follow and understand

## Weaknesses
While the paper is well-written and presents a promising approach, there are some weaknesses to consider:
* The reliance on a pre-trained database of CDR structures may limit the applicability of IgSeek to new or unseen data
* The use of a simple distance metric (RMSD) to evaluate the quality of retrieved structures may not capture all relevant aspects of structural similarity
* The lack of explicit consideration of functional or binding properties of the designed antibodies may limit their potential for therapeutic applications

## Questions
To further improve the paper and address potential concerns, the following questions could be explored:
* How does IgSeek perform on datasets with limited or no structural information, and are there ways to adapt the approach to such scenarios?
* Can the authors provide more insight into the robustness of IgSeek to variations in the input data, such as noise or errors in the CDR structures?
* Are there plans to integrate IgSeek with other antibody design tools or pipelines to enable more comprehensive and functional antibody design workflows?

RATING: 9